ArticleFrontiers in oncology2025
Preoperative assessment of longitudinal extent in hilar cholangiocarcinoma using noninvasive enhanced MR radiomics: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to develop a noninvasive radiomics model based on magnetic resonance imaging (MRI) for accurately predicting the longitudinal extent of hilar cholangiocarcinoma (HCCA), to assist in subsequent surgical decision making. Methods: This study retrospectively collected and analyzed data from patients with HCCA across three medical centers in China. Radiomics quantitative features were extracted from T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and enhanced T1 high-resolution isotropic volume examination (e-THRIVE) sequences. L1 regularization was employed to select features, and three single-sequence radiomics models were developed to predict Bismuth type IV of HCCA. To improve the predictive accuracy for Bismuth type IV, the fusion model integrating the three single-sequence models was constructed. The performance of these models was evaluated comprehensively, and the optimal radiomics model for predicting longitudinal extent was identified. Results: A total of 154 patients with HCCA were included in the analysis. The radiomics models based on T2WI, DWI, and e-THRIVE sequences demonstrated predictive capabilities, with AUC values in the training set of 0.867, 0.923, and 0.872, respectively, and AUC values in the test set of 0.809, 0.823, and 0.808, respectively. The fusion model, which combined features from all three sequences, achieved superior predictive performance, with an AUC of 0.980 in the training set and 0.907 in the test set. This model demonstrated robust potential for predicting whether the HCCA was classified as Bismuth type IV. Conclusion: The multi-sequence MRI-based radiomics model can effectively predict Bismuth type IV of HCCA, assisting in clinical surgical decision-making, facilitating R0 resection to improve the prognosis of patients with HCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.